Placing COURAGE in Context: Review of the Recent Literature on Managing Stable Coronary Artery Disease

Coylewright, Megan; Blumenthal, Roger S.; Post, Wendy
July 2008
Mayo Clinic Proceedings;Jul2008, Vol. 83 Issue 7, p799
Academic Journal
Coronary artery disease (CAD) is the leading cause of death in the United States, but prevention and intervention efforts are lowering mortality. This progress is being undercut by rising rates of obesity and diabetes, and adherence to evidence-based prevention efforts is less than ideal. Many patients with CAD who are asymptomatic or have minimal symptoms undergo percutaneous coronary intervention (PCI) each year, even though PCI has not been demonstrated to improve survival for this group. Motivated by the recent controversy surrounding the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, we reviewed randomized clinical trials with follow-up published in the past decade comparing medical management with revascularization for stable CAD to provide a context for the COURAGE trial. We searched for relevant studies published from January 1, 1997, until the date of electronic publication of the COURAGE study results, March 26, 2007; references cited in the COURAGE publication were also reviewed. Evidence shows that PCI does not decrease mortality or risk of myocardial infarction over optimal medical or lifestyle therapy in patients with chronic stable CAD. In published studies, early benefits in angina control afforded by revascularization wane over time; this could change with modern interventional therapies. The final word is not that medical therapy is superior for all patients, but that optimizing medical and lifestyle therapy is appropriate as an initial management strategy for most patients who do not have unstable or disabling symptoms. It is essential that systems are set in place to make the medical management of patients with CAD second nature; this focus could be one of the most powerful results of the COURAGE trial.


Related Articles

  • The effect of a decision aid intervention on decision making about coronary heart disease risk reduction: secondary analyses of a randomized trial. Sheridan, Stacey L.; Draeger, Lindy B.; Pignone, Michael P.; Rimer, Barbara; Bangdiwala, Shrikant I.; Cai, Jianwen; Gizlice, Ziya; Keyserling, Thomas C.; Simpson Jr., Ross J. // BMC Medical Informatics & Decision Making;2014, Vol. 14 Issue 1, p2 

    Background Decision aids offer promise as a practical solution to improve patient decision making about coronary heart disease (CHD) prevention medications and help patients choose medications to which they are likely to adhere. However, little data is available on decision aids designed to...

  • More Intensive Glycemic Control Reduces Nonfatal Myocardial Infarction But Not All-Cause Mortality. Pignone, Michael // Clinical Diabetes;Spring2010, Vol. 28 Issue 2, p87 

    In this article, the author discusses a study related to role of glycemic control in myocardial infarction and deaths related to it, conducted by K.K. Ray and colleagues. The author is critical of the evidences used for reduction of cardiovascular attacks with controlled glycemic. He states that...

  • The Healthy Heart Report. Sahley, Billie J. // MMRC Health Educator Reports;2008, p1 

    The article specifies the factors to consider in preventing coronary heart disease (CHD). Results of a social survey in the U.S. reveal the alarming rate of people affected by CHD which prompts the medical industry to intensify efforts to increase awareness about the disease. Preventive measures...

  • Experts debate using risk or expected benefit for determining when to start stain therapy.  // Formulary;Nov99, Vol. 34 Issue 11, p908 

    Presents perspectives on the use of statin therapy for primary prevention of coronary artery diseases. Initiation of statins for primary prevention guided by the risk of future cardiovascular events; Multifactorial approach to guide treatment decisions; Statin therapy guided by the expected...

  • Use of aspirin in primary prevention is questioned.  // Nursing Standard;7/22/2009, Vol. 23 Issue 46, p16 

    The article discusses a report titled "Aspirin In the Primary and Secondary Prevention of Vascular Disease: Collaborative Meta-Analysis of Individual Participant Data From Randomised Trials," by the Antithrombotic Trialists' (ATT) Collaboration published in a 2009 issue of "The Lancet." Topics...

  • Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity. Galal, Aya; El-Bakly, Wesam; Al Haleem, Ekram; El-Demerdash, Ebtehal; El-Bakly, Wesam M; Al Haleem, Ekram Nemr Abd // Cancer Chemotherapy & Pharmacology;Feb2016, Vol. 77 Issue 2, p309 

    Purpose: Doxorubicin (DOX) is an effective anticancer drug; however, its clinical use is limited by its cardiotoxic effect. Adenosine was proved to mediate anti-inflammatory effects and protected from myocardial ischemia/reperfusion injury. So the present work was designed to...

  • Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial.  // JAMA: Journal of the American Medical Association;1/26/2005, Vol. 293 Issue 4, p437 

    Context Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered...

  • Pets that heal.  // Consumer Reports on Health;Oct93, Vol. 5 Issue 10, p109 

    Suggests the role of pets in fighting coronary heart disease. Research from Purdue University showing lower blood pressure and cholesterol levels of pet owners; Quality of relationships with other people of pet owners; Alleviation of psychological and social factors.

  • Ticagrelor's efficacy outweighs generic clopidogrel's low price.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p3 

    The article focuses on a study of the cost effectiveness of using ticagrelor in the secondary prevention of acute coronary syndromes (ACS) compared with clopidogrel treatment conducted by D. J. Crespin and colleagues and published in the June 2011 issue of "Value in Health."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics